Does the media favor ACRS or IDYA?

In the previous week, IDEAYA Biosciences had 4 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 11 mentions for IDEAYA Biosciences and 7 mentions for Aclaris Therapeutics. IDEAYA Biosciences' average media sentiment score of 1.37 beat Aclaris Therapeutics' score of 1.03 indicating that IDEAYA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend GMTX or ACRS?

Aclaris Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 91.35%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aclaris Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.13

Is GRAL or ACRS more profitable?

GRAIL has a net margin of -236.95% compared to Aclaris Therapeutics' net margin of -921.50%. GRAIL's return on equity of -15.88% beat Aclaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets GRAIL -236.95% -15.88% -14.02% Aclaris Therapeutics -921.50% -61.65% -42.41%

Does the media prefer GRAL or ACRS?

In the previous week, Aclaris Therapeutics had 1 more articles in the media than GRAIL. MarketBeat recorded 7 mentions for Aclaris Therapeutics and 6 mentions for GRAIL. GRAIL's average media sentiment score of 1.20 beat Aclaris Therapeutics' score of 1.03 indicating that GRAIL is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ACRS or VCYT?

In the previous week, Veracyte had 9 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 16 mentions for Veracyte and 7 mentions for Aclaris Therapeutics. Veracyte's average media sentiment score of 1.08 beat Aclaris Therapeutics' score of 1.03 indicating that Veracyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 12 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to QURE or ACRS?

In the previous week, Aclaris Therapeutics had 4 more articles in the media than uniQure. MarketBeat recorded 7 mentions for Aclaris Therapeutics and 3 mentions for uniQure. uniQure's average media sentiment score of 1.21 beat Aclaris Therapeutics' score of 1.03 indicating that uniQure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aclaris Therapeutics (ACRS) Competitors

$6.01 -0.15 (-2.44%)

As of 08/28/2026 04:00 PM Eastern

Compare

ACRS vs. IDYA, GMTX, GRAL, VCYT, and QURE

Should you buy Aclaris Therapeutics stock or one of its competitors? Aclaris Therapeutics's main competitors and comparable companies include IDEAYA Biosciences (IDYA), Gemini Therapeutics (GMTX), GRAIL (GRAL), Veracyte (VCYT), and uniQure (QURE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aclaris Therapeutics compare to IDEAYA Biosciences?

Aclaris Therapeutics (NASDAQ:ACRS) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Aclaris Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.1, suggesting that its share price is 110% less volatile than the broader market.

In the previous week, IDEAYA Biosciences had 4 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 11 mentions for IDEAYA Biosciences and 7 mentions for Aclaris Therapeutics. IDEAYA Biosciences' average media sentiment score of 1.37 beat Aclaris Therapeutics' score of 1.03 indicating that IDEAYA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aclaris Therapeutics presently has a consensus target price of $11.50, suggesting a potential upside of 91.35%. IDEAYA Biosciences has a consensus target price of $50.13, suggesting a potential upside of 24.97%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Aclaris Therapeutics is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

IDEAYA Biosciences has a net margin of -75.93% compared to Aclaris Therapeutics' net margin of -921.50%. IDEAYA Biosciences' return on equity of -16.73% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%

Aclaris Therapeutics has higher earnings, but lower revenue than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	107.32	-$64.92M	-$0.58	N/A
IDEAYA Biosciences	$234.13M	15.05	-$113.70M	-$1.94	N/A

Summary

Aclaris Therapeutics beats IDEAYA Biosciences on 10 of the 17 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Aclaris Therapeutics (NASDAQ:ACRS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Gemini Therapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -921.50%. Gemini Therapeutics' return on equity of -38.78% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%

Aclaris Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 91.35%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Aclaris Therapeutics had 7 more articles in the media than Gemini Therapeutics. MarketBeat recorded 7 mentions for Aclaris Therapeutics and 0 mentions for Gemini Therapeutics. Aclaris Therapeutics' average media sentiment score of 1.03 beat Gemini Therapeutics' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Aclaris Therapeutics	Positive

Gemini Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

Aclaris Therapeutics has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Aclaris Therapeutics	$7.83M	107.32	-$64.92M	-$0.58	N/A

Summary

Aclaris Therapeutics beats Gemini Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Aclaris Therapeutics compare to GRAIL?

GRAIL (NASDAQ:GRAL) and Aclaris Therapeutics (NASDAQ:ACRS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Aclaris Therapeutics had 1 more articles in the media than GRAIL. MarketBeat recorded 7 mentions for Aclaris Therapeutics and 6 mentions for GRAIL. GRAIL's average media sentiment score of 1.20 beat Aclaris Therapeutics' score of 1.03 indicating that GRAIL is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GRAIL has a net margin of -236.95% compared to Aclaris Therapeutics' net margin of -921.50%. GRAIL's return on equity of -15.88% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-236.95%	-15.88%	-14.02%
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%

Aclaris Therapeutics has lower revenue, but higher earnings than GRAIL. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$165.26M	21.62	-$408.35M	-$9.75	N/A
Aclaris Therapeutics	$7.83M	107.32	-$64.92M	-$0.58	N/A

98.3% of Aclaris Therapeutics shares are owned by institutional investors. 1.8% of GRAIL shares are owned by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

GRAIL currently has a consensus price target of $67.78, indicating a potential downside of 15.28%. Aclaris Therapeutics has a consensus price target of $11.50, indicating a potential upside of 91.35%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

GRAIL has a beta of 3.24, suggesting that its share price is 224% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Summary

Aclaris Therapeutics beats GRAIL on 9 of the 16 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Veracyte?

Aclaris Therapeutics (NASDAQ:ACRS) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Aclaris Therapeutics presently has a consensus price target of $11.50, indicating a potential upside of 91.35%. Veracyte has a consensus price target of $54.33, indicating a potential upside of 25.37%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Aclaris Therapeutics is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Veracyte has a net margin of 20.37% compared to Aclaris Therapeutics' net margin of -921.50%. Veracyte's return on equity of 9.26% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
Veracyte	20.37%	9.26%	8.61%

Veracyte has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	107.32	-$64.92M	-$0.58	N/A
Veracyte	$561.90M	6.20	$66.35M	$1.41	30.74

In the previous week, Veracyte had 9 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 16 mentions for Veracyte and 7 mentions for Aclaris Therapeutics. Veracyte's average media sentiment score of 1.08 beat Aclaris Therapeutics' score of 1.03 indicating that Veracyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	12 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aclaris Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Veracyte has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market.

98.3% of Aclaris Therapeutics shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Veracyte beats Aclaris Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Aclaris Therapeutics compare to uniQure?

uniQure (NASDAQ:QURE) and Aclaris Therapeutics (NASDAQ:ACRS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Aclaris Therapeutics has a net margin of -921.50% compared to uniQure's net margin of -1,350.73%. Aclaris Therapeutics' return on equity of -61.65% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%

uniQure currently has a consensus price target of $65.00, indicating a potential upside of 33.42%. Aclaris Therapeutics has a consensus price target of $11.50, indicating a potential upside of 91.35%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Aclaris Therapeutics has lower revenue, but higher earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	209.92	-$198.97M	-$4.01	N/A
Aclaris Therapeutics	$7.83M	107.32	-$64.92M	-$0.58	N/A

In the previous week, Aclaris Therapeutics had 4 more articles in the media than uniQure. MarketBeat recorded 7 mentions for Aclaris Therapeutics and 3 mentions for uniQure. uniQure's average media sentiment score of 1.21 beat Aclaris Therapeutics' score of 1.03 indicating that uniQure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.8% of uniQure shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 4.7% of uniQure shares are owned by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

uniQure has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

Summary

Aclaris Therapeutics beats uniQure on 11 of the 17 factors compared between the two stocks.

Get Aclaris Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACRS vs. The Competition

Export

Metric	Aclaris Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$840.34M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-10.36	11.62	273.16	25.45
Price / Sales	107.32	1,293.26	604.87	76.92
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	6.75	16.53	12.98	6.14
Net Income	-$64.92M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-6.24%	-0.31%	0.13%	-0.80%
1 Month Performance	12.97%	9.80%	7.08%	4.13%
1 Year Performance	211.40%	55.66%	24.67%	15.17%

Aclaris Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACRS Aclaris Therapeutics	2.3718 of 5 stars	$6.01 -2.4%	$11.50 +91.3%	+211.4%	$840.34M	$7.83M	N/A	100	Positive News
IDYA IDEAYA Biosciences	3.0964 of 5 stars	$40.04 +0.9%	$50.13 +25.2%	+63.4%	$3.52B	$234.13M	N/A	80	News Coverage Gap Up
GMTX Gemini Therapeutics	N/A	$79.81 +1.2%	N/A	+33.5%	$3.46B	N/A	N/A	30
GRAL GRAIL	1.1581 of 5 stars	$76.58 -3.7%	$67.78 -11.5%	+144.0%	$3.42B	$165.26M	N/A	1,360	Gap Up
VCYT Veracyte	4.4854 of 5 stars	$41.47 -2.0%	$54.33 +31.0%	+42.8%	$3.33B	$561.90M	29.41	790	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACRS) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aclaris Therapeutics (ACRS) Competitors

ACRS vs. IDYA, GMTX, GRAL, VCYT, and QURE

How does Aclaris Therapeutics compare to IDEAYA Biosciences?

Summary

How does Aclaris Therapeutics compare to Gemini Therapeutics?

Summary

How does Aclaris Therapeutics compare to GRAIL?

Summary

How does Aclaris Therapeutics compare to Veracyte?

Summary

How does Aclaris Therapeutics compare to uniQure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS vs. The Competition

Aclaris Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aclaris Therapeutics (ACRS) Competitors

ACRS vs. IDYA, GMTX, GRAL, VCYT, and QURE

How does Aclaris Therapeutics compare to IDEAYA Biosciences?

Which has more volatility & risk, ACRS or IDYA?

Does the media favor ACRS or IDYA?

Do analysts prefer ACRS or IDYA?

Do insiders & institutionals hold more shares of ACRS or IDYA?

Is ACRS or IDYA more profitable?

Which has stronger earnings and valuation, ACRS or IDYA?

Summary

How does Aclaris Therapeutics compare to Gemini Therapeutics?

Is GMTX or ACRS more profitable?

Do analysts recommend GMTX or ACRS?

Do institutionals & insiders hold more shares of GMTX or ACRS?

Does the media refer more to GMTX or ACRS?

Which has more risk and volatility, GMTX or ACRS?

Which has stronger valuation and earnings, GMTX or ACRS?

Summary

How does Aclaris Therapeutics compare to GRAIL?

Does the media prefer GRAL or ACRS?

Is GRAL or ACRS more profitable?

Which has better valuation and earnings, GRAL or ACRS?

Do insiders and institutionals have more ownership in GRAL or ACRS?

Do analysts recommend GRAL or ACRS?

Which has more risk & volatility, GRAL or ACRS?

Summary

How does Aclaris Therapeutics compare to Veracyte?

Do analysts recommend ACRS or VCYT?

Is ACRS or VCYT more profitable?

Which has preferable valuation & earnings, ACRS or VCYT?

Does the media refer more to ACRS or VCYT?

Which has more volatility & risk, ACRS or VCYT?

Do institutionals & insiders believe in ACRS or VCYT?

Summary

How does Aclaris Therapeutics compare to uniQure?

Is QURE or ACRS more profitable?

Do analysts recommend QURE or ACRS?

Which has preferable earnings & valuation, QURE or ACRS?

Does the media refer more to QURE or ACRS?

Do institutionals and insiders believe in QURE or ACRS?

Which has more risk & volatility, QURE or ACRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS vs. The Competition

Aclaris Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools